Patents Assigned to Brassica Foundation for Chemoprotection Research, Inc.
  • Prevention and treatment of oxidative stress disorders by gluthathione and phase II detoxification enzymes
    Patent number: 8709406
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 29, 2014
    Assignee: Brassica Foundation for Chemoprotection Research, Inc.
    Inventors: Xiangqun Gao, Albena T. Dinkova-Kostova, Paul Talalay
  • Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
    Patent number: 8303949
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracelluar levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: November 6, 2012
    Assignee: Brassica Foundation for Chemoprotection Research, Inc.
    Inventors: Xiangqun Gao, Albena T. Dinkova-Kostova, Paul Talalay
  • Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
    Patent number: 7407986
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: August 5, 2008
    Assignee: Brassica Foundation for Chemoprotection Research, Inc.
    Inventors: Xiangqun Gao, Albena T. Dinkova-Kostova, Paul Talalay
  • Treatment of with isothiocyanates
    Patent number: 7402569
    Abstract: The present invention relates to methods of preventing or inhibiting the growth of Helicobacter through the use of a composition that comprises a glucosinolate, an isothiocyanate or a derivative or metabolite thereof. The present invention also relates to methods of preventing or treating persistent chronic gastritis, ulcers and/or stomach cancer in subjects at risk for, or in need of treatment thereof.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: July 22, 2008
    Assignee: Brassica Foundation for Chemoprotection Research, Inc.
    Inventor: Jed W. Fahey
  • Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
    Publication number: 20050063965
    Abstract: The present invention generally relates to the field of treating oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in animal tissue. The present invention also relates to the field of protecting a subject from oxidative stress disorders by administering a pharmaceutically effective amount of a compound that elevates the intracellular levels of glutathone or intracellular levels of at least one Phase II detoxification enzyme in the subject. The present invention also relates to a pharmaceutical composition useful for the treatment of oxidative stress disorders.
    Type: Application
    Filed: December 18, 2002
    Publication date: March 24, 2005
    Applicant: Brassica Foundation for Chemoprotection Research Inc
    Inventors: Xiangqun Gao, Albena Dinkova-Kostova, Paul Talalay